The list below, as well as information from Daiichi Sankyo Group-sponsored clinical trials registered and published on registries such as ClinicalTrials.gov, EU-Clinical Trial Register and Japan Registry of Clinical Trials (jRCT), are provided for informational purposes only, and are not intended to promote any product. Clinical study reports provide results known at the time of the study completion and analysis. Therefore, the results provided may not provide either a complete or current review of the safety and efficacy of the pharmaceutical product studied.
  Health care providers and patients should refer to the current product labeling for detailed information on approved indications in their country or region.
  This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medication is the correct or best treatment option for a particular patient. If you have questions, please consult with a health care professional.



Search by Disease Name, Project Code, Generic Name or Study Code

  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Q

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Protocol Access to Study Results and
Plain Language Summaries
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-A-J201 NCT02984995
JapicCTI-163441
jRCT2080223386
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Quizartinib VANFLYTA® Acute Myeloid Leukemia AC220-A-J102 NCT02834390
JapicCTI-163309
jRCT2080223254
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Quizartinib VANFLYTA® Relapsed or Refactory Acute Myeloid Leukemia AC220-A-J101 NCT02675478
JapicCTI-163142
jRCT2080223088
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)

T

Generic Name / Project Code Trade Name Medical Condition Study Code Access to Study Protocol Access to Study Results and
Plain Language Summaries
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DESTINY-Breast01
DS8201-A-U201
NCT03248492
2016-004986-18
JapicCTI-173693
jRCT2080223637
Tabulated Results
(CT.gov)
(EU-CTIS)
Plain Language Summary
(EN) (JP)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Breast Cancer DS8201-A-J102 NCT03366428
JapicCTI-173791
jRCT2080223735
Tabulated Results
(CT.gov)
Summary Results
(jRCT)
Plain Language Summary
(EN) (JP)
Trastuzumab Deruxtecan
(DS-8201)
ENHERTU® Advanced Solid Malignant Tumors DS8201-A-J101 NCT02564900
JapicCTI-152978
jRCT2080222926
Tabulated Results
(CT.gov)
Plain Language Summary
(EN) (JP)